Maximum Strength Dm Max

Description

This product contains Dextromethorphan HBr, a cough suppressant, and Guaifenesin, an expectorant, formulated to address symptoms of congestion and cough. It is indicated for the control of cough, thinning and loosening mucus, and relieving chest congestion. The product is recommended for individuals aged 12 years and older. It is available in a liquid dosage form, with a volume of 6 fluid ounces (177 mL). The National Drug Code (NDC) for this product is 37808-518-25, and it is manufactured by H-E-B®. This formulation is classified as Maximum Strength DM MAX.

Uses and Indications

This drug is indicated for the relief of cough associated with minor throat and bronchial irritation due to colds. It helps to loosen phlegm (mucus) and thin bronchial secretions, facilitating drainage of the bronchial tubes.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Patients should take the medication only as recommended. It is advised to utilize the provided dosage cup for accurate measurement. The dosage is specified in milliliters (mL), and it is crucial not to exceed 6 doses within any 24-hour period.

For adults and children aged 12 years and older, the recommended dosage is 20 mL administered every 4 hours as needed. The use of this medication is not recommended for children under 12 years of age.

Contraindications

There are no specific contraindications identified for this product. However, it is advised not to exceed the recommended dosage. Additionally, if a cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or a persistent headache, discontinue use and consult a healthcare professional.

Warnings and Precautions

The use of this product is contraindicated in children under 12 years of age. Healthcare professionals should ensure that patients are aware of this restriction to prevent potential adverse effects in younger populations.

Patients currently taking a prescription monoamine oxidase inhibitor (MAOI), which includes certain medications for depression, psychiatric or emotional conditions, or Parkinson's disease, should not use this product. Additionally, it is essential to refrain from using this product for at least two weeks after discontinuing an MAOI. If there is uncertainty regarding the presence of an MAOI in a patient's current medication regimen, it is advisable to consult a healthcare provider or pharmacist prior to use.

In the event of an overdose, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay to ensure appropriate management.

Patients should be instructed to discontinue use and consult a healthcare professional if a cough persists for more than seven days, recurs, or is accompanied by fever, rash, or a persistent headache. These symptoms may indicate a more serious underlying condition that requires further evaluation and intervention.

Side Effects

Patients should be aware of several important warnings and adverse reactions associated with the use of this product. It is contraindicated for children under 12 years of age. Additionally, patients should not use this product if they are currently taking a prescription monoamine oxidase inhibitor (MAOI) or have taken one within the past two weeks. MAOIs are commonly prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. If patients are uncertain whether their prescription medication contains an MAOI, they should consult a healthcare professional before use.

In terms of adverse reactions, patients are advised to discontinue use and seek medical attention if a cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a serious underlying condition. Furthermore, patients should consult a doctor prior to use if they have a cough that is chronic, such as that associated with smoking, asthma, chronic bronchitis, or emphysema. It is also recommended that patients seek medical advice if they experience a cough that produces excessive phlegm (mucus).

Drug Interactions

The concomitant use of this product with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. MAOIs are typically prescribed for the treatment of depression, certain psychiatric conditions, or Parkinson's disease. Patients should not take this product while on MAOIs or for a minimum of two weeks following the discontinuation of an MAOI. It is essential for patients to consult with a healthcare professional, such as a doctor or pharmacist, to confirm whether their current prescription includes an MAOI before initiating treatment with this product.

Packaging & NDC

Below are the non-prescription pack sizes of Maximum Strength Dm Max (dextromethorphan hydrobromide, guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not use this medication. For adolescents aged 12 years and older, the recommended dosage is 20 mL every 4 hours.

It is essential to keep this medication out of reach of children. In the event of an overdose, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

Geriatric Use

Elderly patients should be aware that this product is not indicated for use in children under 12 years of age. Prior to use, it is advisable for geriatric patients to consult a healthcare provider if they have a cough that is chronic or persistent, particularly in cases associated with smoking, asthma, chronic bronchitis, or emphysema. Additionally, those experiencing a cough accompanied by excessive phlegm (mucus) should seek medical advice before using this product.

When utilizing this medication, elderly patients must adhere strictly to the recommended dosage and should not exceed the directed amount. It is crucial for geriatric patients to discontinue use and consult a healthcare professional if the cough persists for more than 7 days, recurs, or is accompanied by symptoms such as fever, rash, or a persistent headache, as these may indicate a serious underlying condition.

Furthermore, elderly patients who are pregnant or breastfeeding should seek guidance from a health professional prior to using this product to ensure safety for both themselves and their child.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is essential to evaluate the potential risks and benefits associated with the use of this drug during pregnancy and lactation. Healthcare providers should consider the available data and individual patient circumstances when advising on the use of this medication in these populations.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor patients closely for any signs or symptoms that may arise following an overdose. Common symptoms may include, but are not limited to, alterations in consciousness, cardiovascular instability, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Supportive care is the cornerstone of management, which may include the following steps:

1. Assessment: Conduct a thorough evaluation of the patient's clinical status, including vital signs and level of consciousness.

2. Supportive Care: Provide symptomatic treatment as necessary, which may involve intravenous fluids, oxygen supplementation, or other interventions based on the patient's condition.

3. Decontamination: If the overdose is recent and the patient is alert, activated charcoal may be considered to limit further absorption of the substance.

4. Consultation: Engage with a poison control center or toxicology specialist for guidance on specific antidotes or advanced management strategies, if applicable.

Healthcare professionals should remain vigilant and prepared to implement these measures promptly to mitigate the potential effects of an overdose.

Nonclinical Toxicology

There is currently no available information regarding teratogenic or non-teratogenic effects associated with the compound. Additionally, no data has been provided concerning nonclinical toxicology, including animal pharmacology and toxicology. As such, a comprehensive assessment of these aspects cannot be made at this time.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Patients should be advised to keep this product out of reach of children. In the event of an overdose, it is crucial to seek medical assistance or contact a Poison Control Center immediately.

Healthcare providers should instruct patients to discontinue use and consult a doctor if their cough persists for more than 7 days, returns, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a serious condition.

Patients must be reminded not to exceed the recommended dosage when using this product. It is also important for healthcare providers to encourage patients to consult a doctor prior to use if they have a cough that is chronic or lasts for an extended period, particularly in cases associated with smoking, asthma, chronic bronchitis, or emphysema. Additionally, patients should be advised to seek medical guidance if their cough is accompanied by excessive phlegm (mucus).

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a temperature range of 15-30°C (59-86°F). Refrigeration is not permitted, as it may compromise the integrity of the product. Proper handling and storage conditions must be adhered to in order to maintain product efficacy and safety.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Maximum Strength Dm Max, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)